Analyst Price Targets On PureTech Health (LON:PRTC)


Currently 5 brokers are covering PureTech Health (LON:PRTC), 5 rate it “Strong Buy”, 0 “Buy”, 0 “Sell”, 0 “Strong Sell”, while 0 “Neutral”.

Below are the most recently updated broker updates which include ratings and price targets for PureTech Health (LON:PRTC) from a range of analyst research notes.

06/04/2017 – Broker: N 1 Singer Rating: Buy reiteration

06/04/2017 – Broker: Numis Securities Rating: Buy New Target: 246.00p reiteration

24/03/2017 – Broker: Numis Securities Rating: Buy New Target: 220.00p reiteration

21/12/2016 – Broker: numis Rating: Buy New Target: 220.00p reiteration

21/12/2016 – Broker: Jefferies Rating: Buy New Target: 255.00p reiteration

12/12/2016 – Broker: Jefferies Rating: Buy New Target: 255.00p reiteration

07/09/2016 – Broker: numis Rating: Buy New Target: 220.00p reiteration

16/08/2016 – Broker: numis Rating: Buy New Target: 206.00p reiteration

02/06/2016 – Broker: numis Rating: Buy New Target: 206.00p reiteration

02/06/2016 – Broker: Jefferies Rating: Buy New Target: 235.00p reiteration

The average price target from the most recently released broker research reports is 229.22

The stock increased +0.00% (+0.00) during the last trading session, reaching 115.50 and roughly 201949 shares were bought or sold by traders. PureTech Health (LON:PRTC) has decreased by -11.83% over 12 months.


Error parsing: Query returned empty response

Receive PureTech Health News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health with MarketBeat.com's FREE daily email newsletter.